IMRX Immuneering Corp: institutional ownership and insider trading
120 funds reported holding $194M of Immuneering Corp in their latest 13F filings; in Q2 2026 funds net bought $40.7M, with 40 new positions and 20 funds selling out; over the last 12 months insiders bought $270K and sold $0 on the open market.
IMRX revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$17.3M, EPS -0.27
- Quarter ended Mar 31, 2026: revenue n/a, net income −$13.5M, EPS -0.21
- Quarter ended Dec 31, 2025: revenue n/a, net income −$11.6M, EPS -0.07
- Quarter ended Sep 30, 2025: revenue n/a, net income −$15.0M, EPS -0.38
Famous investors holding IMRX
- Ken Griffin (Citadel Advisors): $2.60M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $1.65M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $1.44M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $1.02M, 0.0% of the portfolio
Largest institutional holders of IMRX
- FMR LLC — $48.4M
- BlackRock, Inc. (BLK) — $21.8M
- VANGUARD GROUP INC — $16.9M
- Sanofi (SNY, SNYNF) — $13.5M
- VANGUARD CAPITAL MANAGEMENT LLC — $11.4M
- PRICE T ROWE ASSOCIATES INC /MD/ — $9.66M
- GEODE CAPITAL MANAGEMENT, LLC — $6.84M
- STATE STREET CORP (STT, STT-PG) — $5.00M
- DCF Advisers, LLC — $3.94M
- MARSHALL WACE, LLP — $3.65M
Recent IMRX insider trades
- Jun 23, 2026: Zeskind Benjamin J. bought 2,400 shares ($10.9K)
- Jun 15, 2026: Hall Brett Matthew bought 6,035 shares ($25.0K)
- Jan 16, 2026: Brakewood Harold Eugene bought 5,250 shares ($25.0K)
- Jan 15, 2026: Schall Thomas J. bought 21,645 shares ($101K)
5%+ owners
- BlackRock, Inc.: 6.7% (Schedule 13G, filed Jul 28, 2026)